Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.
about
Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomicsInvestigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Quantitative targeted proteomics for membrane transporter proteins: method and application.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers.Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease.Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modelling and simulation.Critical Issues and Optimized Practices in Quantification of Protein Abundance Level to Determine Interindividual Variability in DMET Proteins by LC-MS/MS Proteomics.Role of Hepatic Drug Transporters in Drug Development.Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach.
P2860
Q26851693-C8FF68A4-C1D4-4F4C-A9C9-CB35D75D5DD6Q33581531-E0FBB2C5-512A-4480-BF1D-DCA8CA66A69BQ33803962-8014A64D-8D0E-48D4-96F7-5B70314224DEQ34571070-21CE8652-3B40-453E-A1EA-7AFB381C6477Q35088420-4DECF78C-E868-474C-8E54-077CD5307AF7Q35560052-1BE600C6-4291-4923-BAED-515F2BF2D74FQ36167561-E75A7B40-8240-4641-B3B4-C5973C645BF2Q38214334-E09B3B78-1350-4520-B900-A3BAB8FDD6A2Q38233298-1D389024-890D-4149-BCF6-96E623988E71Q38793280-E470B32A-A91D-45EB-ABFA-6D2FBC6F9CC3Q38798449-644ADB58-F7B1-49FC-8E49-F679DE66F9CFQ38888365-CD594B38-1BB7-4F65-B8E7-B2E885311169Q40129655-CAA685B2-D993-4208-87F7-F4B44E4809BCQ40916355-335B93CC-4A60-4889-AEE5-1E6ABACC9277Q41451841-F6004E0E-C5C3-4BA1-89EE-8563024613F4Q47305834-C6457F37-3D8C-454C-BCB8-1EECDAABB43DQ47917027-816DA471-09F1-4339-88E7-FCB48AEC90B7Q51659233-52E69F86-A0B8-4A18-9A08-12490DFC6C6DQ53188214-D9B271A6-32FA-4BA2-A728-749EF3D53221
P2860
Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Quantitative assessment of the ...... pitavastatin and fluvastatin.
@en
Quantitative assessment of the ...... pitavastatin and fluvastatin.
@nl
type
label
Quantitative assessment of the ...... pitavastatin and fluvastatin.
@en
Quantitative assessment of the ...... pitavastatin and fluvastatin.
@nl
prefLabel
Quantitative assessment of the ...... pitavastatin and fluvastatin.
@en
Quantitative assessment of the ...... pitavastatin and fluvastatin.
@nl
P2093
P2860
P356
P1476
Quantitative assessment of the ...... , pitavastatin and fluvastatin
@en
P2093
Ayman F Ei-Kattan
Charles J Rotter
Manthena V Varma
Mary Piotrowski
P2860
P304
P356
10.1002/BDD.1861
P577
2013-10-03T00:00:00Z